Video

Peter Lio, MD: Managing and Treating Itch

Author(s):

Peter Lio, MD, discusses conventional therapeutic options for pruritus.

The treatments for itch can be just as numerous as the underlying causes.

In the latest episode of Derm Discussions, Peter Lio, MD, Clinical Assistant Professor of Dermatology & Pediatrics, Northwestern University Feinberg School of Medicine, discussed the different ways itch can be treated.

“I think the first thing is that we want to see as best we can to try to understand what is mediating itch,” Lio said. “In those 4 categories, is there an underlying dermatologic disease—particularly inflammatory disease—that we can approach? Is there some kind of a neuropathy? Do we need to focus on nerves? Is it psychogenic? Is it systemic?”

He acknowledged that treatment can be especially difficult if the clinician is faced with pruritis sin materia — or itch without a rash.

In this instance, work-up and screenings are warranted; and even then, patients may still find themselves in a position where the symptom cannot be managed.

Lio described his therapeutic ladder, which begins with topical medications and proceeds with “safe systemics” and more powerful systemics.

He also explained his approach as integrative, sometimes incorporating topical corticosteroids if the underlying cause is mediated by inflammation or the immune system. Depending on cause, other options include calcineurin inhibitors and topical anesthetics.

Options for systemic chronic itch include antihistamines, gabapentin, antidepressants, NK1 inhibitors, opioid modulators, and naltrexone.

Listen to the full podcast episode below:

Related Videos
John Kane, MD | Credit: Northwell Health
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Skin of Color Savvy: The Art and Science of Treating Patients of Color
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
© 2025 MJH Life Sciences

All rights reserved.